World's Best Scientists 2026 revealed!

Yongqian Shu publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Yongqian Shu sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

The last bar groups every scientist with 1,796 publications or more.

Yongqian Shu D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Yongqian Shu sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

The last bar groups every scientist with 217 D-Index or more.

Overview

Yongqian Shu is affiliated with Nanjing Medical University in China and has contributed extensively to the fields of medicine and biochemistry, genetics, and molecular biology. Their research primarily focuses on oncology, pulmonary and respiratory medicine, molecular biology, cancer research, and surgery.

Their work covers a range of main topics including:

  • Lung Cancer Treatments and Mutations
  • Lung Cancer Research Studies
  • Cancer Immunotherapy and Biomarkers
  • Colorectal Cancer Treatments and Studies
  • Gastric Cancer Management and Outcomes
  • Lung Cancer Diagnosis and Treatment
  • Cancer Genomics and Diagnostics

Yongqian Shu has published in prominent venues, with frequent publications in:

  • Journal of Clinical Oncology
  • SSRN Electronic Journal
  • Journal of Thoracic Oncology
  • Cancer Cell
  • Annals of Oncology

Their notable recent papers include:

  • "Exosomal circSHKBP1 promotes gastric cancer progression via regulating the miR-582-3p/HUR/VEGF axis and suppressing HSP90 degradation" (2020), Molecular Cancer
  • "Bevacizumab plus erlotinib in Chinese patients with untreated, EGFR-mutated, advanced NSCLC (ARTEMIS-CTONG1509): A multicenter phase 3 study" (2021), Cancer Cell
  • "Anlotinib for previously treated advanced or metastatic esophageal squamous cell carcinoma: A double-blind randomized phase 2 trial" (2021), Cancer Medicine
  • "The evolving landscape of N6-methyladenosine modification in the tumor microenvironment" (2021), Molecular Therapy
  • "Benmelstobart, anlotinib and chemotherapy in extensive-stage small-cell lung cancer: a randomized phase 3 trial" (2024), Nature Medicine

Collaborations have played a role in their career, with frequent co-authors including:

  • Jiuwei Cui (8 collaborations)
  • Ying Cheng (6 collaborations)
  • Zhiyong Ma (6 collaborations)
  • Yi-Long Wu (5 collaborations)
  • Kangsheng Gu (5 collaborations)

Best Publications

  • Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial

    Luis Paz-Ares;Mikhail Dvorkin;Yuanbin Chen;Niels Reinmuth

  • Role of hypoxia in cancer therapy by regulating the tumor microenvironment

    Xinming Jing;Fengming Yang;Chuchu Shao;Ke Wei

  • Serum MicroRNA Signatures Identified in a Genome-Wide Serum MicroRNA Expression Profiling Predict Survival of Non–Small-Cell Lung Cancer

    Zhibin Hu;Xi Chen;Yang Zhao;Tian Tian

  • Pyroptosis: A new frontier in cancer.

    Yuan Fang;Shengwang Tian;Yutian Pan;Wei Li

  • Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study.

    Jing Huang;Jianming Xu;Yun Chen;Wu Zhuang

  • P53-regulated long non-coding RNA TUG1 affects cell proliferation in human non-small cell lung cancer, partly through epigenetically regulating HOXB7 expression

    Zhang Eb;Yin Dd;Sun M;Kong R

  • A genome-wide association study identifies two new lung cancer susceptibility loci at 13q12.12 and 22q12.2 in Han Chinese

    Zhibin Hu;Chen Wu;Yongyong Shi;Huan Guo

  • miR-181b modulates multidrug resistance by targeting BCL2 in human cancer cell lines

    Wei Zhu;Xia Shan;Tongshan Wang;Yongqian Shu

  • A Functional Genetic Variant in microRNA-196a2 Is Associated with Increased Susceptibility of Lung Cancer in Chinese

    Tian Tian;Yongqian Shu;Jiaping Chen;Zhibin Hu

  • Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial.

    Caicun Zhou;Gongyan Chen;Yunchao Huang;Jianying Zhou

  • Deregulated expression of miR-21, miR-143 and miR-181a in non small cell lung cancer is related to clinicopathologic characteristics or patient prognosis

    Wen Gao;Yue Yu;Hailong Cao;Hua Shen

  • Effect of Fruquintinib vs Placebo on Overall Survival in Patients With Previously Treated Metastatic Colorectal Cancer: The FRESCO Randomized Clinical Trial.

    Jin Li;Jin Li;Shukui Qin;Rui Hua Xu;Lin Shen

  • CircRNAs in cancer metabolism: a review

    Tao Yu;Yanfen Wang;Yu Fan;Na Fang

  • MiR-21 overexpression in human primary squamous cell lung carcinoma is associated with poor patient prognosis.

    Wen Gao;Hua Shen;Lingxiang Liu;Jian Xu

  • Multiple functions of m 6 A RNA methylation in cancer

    Yutian Pan;Pei Ma;Yu Liu;Wei Li

  • Exosomal circSHKBP1 promotes gastric cancer progression via regulating the miR-582-3p/HUR/VEGF axis and suppressing HSP90 degradation

    Mengyan Xie;Tao Yu;Xinming Jing;Ling Ma

  • Decreased expression of the long non-coding RNA FENDRR is associated with poor prognosis in gastric cancer and FENDRR regulates gastric cancer cell metastasis by affecting fibronectin1 expression

    Tong-peng Xu;Ming-de Huang;Rui Xia;Xin-xin Liu

  • Bevacizumab plus capecitabine and cisplatin in Chinese patients with inoperable locally advanced or metastatic gastric or gastroesophageal junction cancer: randomized, double-blind, phase III study (AVATAR study)

    Lin Shen;Jin Li;Jianming Xu;Hongming Pan

  • Comprehensive Characterization of Molecular Differences in Cancer between Male and Female Patients

    Yuan Yuan;Lingxiang Liu;Hu Chen;Yumeng Wang;Yumeng Wang

  • Exosomal miRNAs and miRNA dysregulation in cancer-associated fibroblasts.

    Fengming Yang;Zhiqiang Ning;Ling Ma;Weitao Liu

Frequent Co-Authors

Hongbing Shen
Hongbing Shen Nanjing Medical University
Zhibin Hu
Zhibin Hu Nanjing Medical University
Guangfu Jin
Guangfu Jin Nanjing Medical University
Rui-Hua Xu
Rui-Hua Xu Sun Yat-sen University
Yang Sun
Yang Sun Nanjing University
Jifeng Feng
Jifeng Feng Nanjing Medical University
Jianming Xu
Jianming Xu Zhejiang University
Caicun Zhou
Caicun Zhou Tongji University
Yi-Long Wu
Yi-Long Wu Guangdong Provincial People’s Hospital
Yi Ba
Yi Ba Beijing Institute of Genomics

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring alternative or complementary online degrees can expand your career options in healthcare beyond traditional medical school. Many students pursue advanced online degrees that offer flexibility, affordability, and strong job prospects within the health sector.

For those interested in healthcare leadership, affordable online mha programs provide pathways into management and administration roles across hospitals, clinics, and public health organizations.

Nursing professionals can further their education and advance patient care careers with the best online bsn to dnp programs, equipping them for top nursing practice and leadership positions.

Aspiring pharmacists can benefit from an online pharmd degree, designed for flexibility and accessibility, preparing graduates for diverse pharmacy careers in clinical and community settings.

Additionally, online schools for health information management are ideal for those interested in the increasingly vital field of health data, medical records, and information systems.

Each of these options represents a dynamic pathway to a rewarding healthcare career—often with shorter commitments and lower costs compared to a traditional medical degree.

Best Scientists Citing Yongqian Shu

Trending Scientists

Recently Published Articles